Co-Diagnostics, Inc. (NASDAQ:CODX) reached 56.34% versus a 1-year low price of $0.69. The stock was last seen 24.5% higher, reaching at $1.09 on 7/11/2019. At a recent session, the prices were hovering between $1.0448 and $1.7834. This company shares are 83.49% off its target price of $2 and the current market capitalization stands at $18.36M. The recent change has given its price a 24.55% lead over SMA 50 and -73.86% deficit over its 52-week high. The stock witnessed 28.49% gains, 0.46% gains and -8.83% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CODX’s volatility during a week at 19.1% and during a month it has been found around 10.25%.Co-Diagnostics, Inc. (CODX) Top Holders
Institutional investors currently hold around $2 million or 10.6% in CODX stock. Look at its top three institutional owners: Sabby Management, Llc owns $674 thousand in Co-Diagnostics, Inc., which represents roughly 3.67% of the company’s market cap and approximately 33.7% of the institutional ownership. Similar statistics are true for the second largest owner, Cvi Holdings, Llc, which owns 708,565 shares of the stock are valued at $618 thousand. The third largest holder is Vanguard Group Inc, which currently holds $123 thousand worth of this stock and that ownership represents nearly 0.67% of its market capitalization.
At the end of March reporting period, 6 institutional holders increased their position in Co-Diagnostics, Inc. (NASDAQ:CODX) by some 1,611,787 shares, 3 decreased positions by 27,335 and 2 held positions by 169,464. That puts total institutional holdings at 1,808,586 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 1,500,395 shares while 2 institutional investors sold out their entire positions totaling 24,244 shares.Co-Diagnostics, Inc. (NASDAQ:CODX) Insider Trades
Multiple company employees have indulged in significant insider trading. Co-Diagnostics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Science Officer, 10% Owner Satterfield Brent has acquired 1,305 shares of Co-Diagnostics, Inc. (CODX) in the trading session dated May. 11, 2018. These shares are worth $2,375 and were traded at $1.82 each. The SEC filing shows that Satterfield Brent performed a purchase of 500 shares. The Chief Science Officer, 10% Owner added these shares by way of transaction on May. 03, 2018. The company’s shares were assimilated at $1.91 per share worth to an investment of some $955 to the account of Satterfield Brent.
Chief Science Officer, 10% Owner, Satterfield Brent, purchased 500 common shares of Co-Diagnostics, Inc. (CODX) in the open market. In a transaction dated Apr. 23, 2018, the shares were bought at an average price of $2.02, giving away a sum of $1,010. After this purchase, 2,273,198 common shares of CODX are directly owned by the insider, with total stake valued at $2,477,786.
In the transaction dated Apr. 16, 2018, a great number of shares acquired came courtesy the Chief Science Officer, 10% Owner; Satterfield Brent added a total of 500 shares at an average price of $1.94, amounting to approximately $970. The insider now directly owns 2,272,698 shares worth $2,477,241.
Several analysts have released their opinion on Co-Diagnostics, Inc. (NASDAQ:CODX), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].